<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4236">
  <stage>Registered</stage>
  <submitdate>8/05/2013</submitdate>
  <approvaldate>8/05/2013</approvaldate>
  <nctid>NCT01852292</nctid>
  <trial_identification>
    <studytitle>Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy</studytitle>
    <scientifictitle>Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBKM120H2201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Head and Neck Squamous Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Paclitaxel
Treatment: drugs - Buparlisib
Treatment: drugs - Buparlisib Placebo

Experimental: Buparlisib + Paclitaxel - buparlisib (BKM120) 100 mg daily + Paclitaxel

Placebo Comparator: Buparlisib matching placebo + Paclitaxel - buparlisib matching placebo


Treatment: drugs: Paclitaxel


Treatment: drugs: Buparlisib


Treatment: drugs: Buparlisib Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - To estimate the efficacy of buparlisib in combination with paclitaxel</outcome>
      <timepoint>at 4 weeks after study treatment start</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - To assess the efficacy of the combination with paclitaxel in this patient population in terms of overall survival</outcome>
      <timepoint>every 3 months for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability - frequency and severity of adverse events - To assess the safety and tolerability of buparlisib in combination with paclitaxel in this patient population</outcome>
      <timepoint>on an ongoing basis for a maximum of 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR)</outcome>
      <timepoint>at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Response (TTR)</outcome>
      <timepoint>at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate (DCR)</outcome>
      <timepoint>at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DoR)</outcome>
      <timepoint>at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the global health status/QOL and pain scale scores of the EORTC QLQ-C30 and QLQ-HN35 - Percentage of change</outcome>
      <timepoint>baseline and every 6 weeks after randomization for 2 years .</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to definitive 10% deterioration in the global health status/QOL (quality of life)</outcome>
      <timepoint>baseline, and every 6 weeks after randomization for maximum for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain scale scores of the EORTC QLQ-C30 and QLQ-HN35</outcome>
      <timepoint>baseline, and every 6 weeks after randomization for maximum for 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Sampling - To characterize the pharmacokinetics of buparlisib given in combination with paclitaxel</outcome>
      <timepoint>Cycle 1, Day1 of ecah cycle until Cycle 6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient has histologically/cytologically-confirmed HNSCC.

          -  Patient has archival or fresh tumor tissue for the analysis of PI3K-related
             biomarkers. One tumor block (preferred) or a minimum of 12 unstained slides to be
             provided. Enrollment in the study is contingent on confirmation of an adequate amount
             of tumor tissue.

          -  Patients with recurrent or metastatic disease resistant to platinum-based chemotherapy
             (defined as progression while on platinum-based chemotherapy given in the
             recurrent/metastatic setting). Pretreatment with cetuximab is allowed

          -  Measurable disease as determined by per RECIST criteria v1.1. If the only site of
             measurable disease is a previously irradiated lesion, documented progression of
             disease and a 4 week period since radiotherapy completion is required

          -  Adequate bone marrow function and organ function

          -  ECOG Performance Status = 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has received previous treatment with any AKT, mTOR inhibitors or PI3K pathway
             inhibitors;

          -  Patient treated with more than one prior chemotherapy regimen for recurrent/metastatic
             disease

          -  Patient has symptomatic CNS metastases. Patients with asymptomatic CNS metastases may
             participate in this trial. The patient must have completed any prior local treatment
             for CNS metastases = 28 days prior to the start of study treatment (including
             radiotherapy and/or surgery) and must have stable low dose of corticosteroid therapy;

          -  Patient has not recovered to = grade 1 (except alopecia) from related side effects of
             any prior antineoplastic therapy

          -  Patient has any of the following cardiac abnormalities:symptomatic congestive heart
             failure, history of documented congestive heart failure (New York Heart Association
             functional classification III-IV), documented cardiomyopathy, Left Ventricular
             Ejection Fraction (LVEF) &lt;50% as determined by Multiple Gated acquisition (MUGA) scan
             or echocardiogram (ECHO); myocardial infarction = 6 months prior to enrolment,
             unstable angina pectoris, serious uncontrolled cardiac arrhythmia, symptomatic
             pericarditis, QTcF &gt; 480 msec on the screening ECG (using the QTcF formula);</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>157</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/03/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Novartis Investigative Site - St. Leonards</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyiregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Rajasthan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>West Bengal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kerala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>FI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PA</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>SA</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>TO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>VE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Russia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhniy Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Gen√®ve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taiwan ROC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Songkla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo
      plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a
      platinum therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01852292</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>